



Company Announcement

Friday 1st June, 2007
Melbourne, Australia

Clinuvel board member resigns

Clinuvel Pharmaceuticals Limited (ASX:CUV, XETRA-DAX:UR9) today announced that Dr Terry Winters, a board member for seven years since the inception of Clinuvel as a public company, has announced his resignation as an Executive Director and Board member, effective immediately.

While a strong supporter of the Company, Dr Winters needs to devote more time to his Chairman/CEO position at Vital Therapies and his partner responsibilities at Valley Ventures.

"With the time demands on me from Clinuvel as it enters this very exciting period of pivotal trials and the equally exciting developments at Vital Therapies, I can no longer spend the time needed on both companies. Now that Clinuvel is well financed and managed, this is an excellent time for me to step down", Dr Terry Winters said.

Clinuvel's Chairman, Dr Roger Aston, said:

"Dr Winters has been a valued member of the Board. On behalf of the Board, I thank him for the significant contribution that he has made to Clinuvel and the clinical development of its photo-protective drug, CUV1647."

-END-

For more information contact:

Davina Gunn / Kate Liscombe
Investor Relations
Clinuvel Pharmaceuticals Limited
Tel: +61 3 9660 4900
investorrelations@clinuvel.com

Clinuvel is an Australian biopharmaceutical company focussed on developing its leading drug candidate, CUV1647, for a range of UV-related skin disorders resulting from exposure of the skin to harmful UV radiation. Pharmaceutical research and development involves long lead times and significant risks. Therefore, while all reasonable efforts have been made by Clinuvel to ensure that there is a reasonable basis for all statements made in this document that relate to prospective events or developments (forward-looking statements), investors should note the following:

- actual results may and often will differ materially from these forward-looking statements;
- no assurances can be given by Clinuvel that any stated objectives, outcomes or timeframes in respect of its development programme for CUV1647 can or will be achieved;
- no assurances can be given by Clinuvel that, even if its development programme for CUV1647 is successful, it will obtain regulatory approval for its pharmaceutical products or that such products, if approved for use, will be successful in the market place

Level 13 / 1 Collins Street
Melbourne, Victoria 3000
Australia

T +61 3 9660 4900
F +61 3 9660 4999

clinuvel.com